Fertility tech company VivoPlex Group has moved its headquarters to Oxford, to take advantage of the city’s medtech and digital health cluster.
The company, spun out from Southampton University four years ago, was previously based on Southampton Science Park.
It plans to recruit more staff across manufacturing, quality systems and regulatory affairs roles during the next 12-18 months.
VivoPlex’s wireless, battery-free sensor monitors temperature, pH and oxygen levels for fertility and uterine health purposes.
The firm expects to be able to start a clinical feasibility study, supported by the UK NIHR’s i4i programme, early next year.
It follows the submission of an approval application to the UK Medicines and Healthcare products Regulatory Agency.
A clean room is also being created at Milton Park, ready to start manufacturing the company’s intra-uterine device next year.
The firm has also appointed a new finance director Stuart Webb, who previously worked for primary care organisation Greenbrook Healthcare, InHealth, ORLA Healthcare and Oxford University Press.
VivoPlex chief executive Joanna Smart said: “Our expansion to Oxford is an important milestone in VivoPlex’s development, bringing us the facilities we need to move our intra-uterine biosensor through the next phases of clinical and commercial development.
“Location in this medtech and digital health cluster also provides access to the talent, expertise and funding which will drive our future growth.”
Oxford biotech company e-therapeutics is offering its powerful network-biology-and AI-based drug discovery platform to help tackle the Covid-19 pandemic.
Using its proprietary tech, a biotech company has discovered antibodies leading to the development of drug discovery programmes in kidney disease and cancer.
Researchers in Oxford and Zurich have used artificial intelligence (AI) and computer visualisation technology to detect changes in colon cancer cells that could be connected to the ‘expression’ of some smell-sensing genes.